RT Journal Article
SR Electronic
T1 Whole-Genome Sequencing Analysis Reveals New Susceptibility Loci and Structural Variants Associated with Progressive Supranuclear Palsy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.28.23300612
DO 10.1101/2023.12.28.23300612
A1 Wang, Hui
A1 Chang, Timothy S
A1 Dombroski, Beth A
A1 Cheng, Po-Liang
A1 Patil, Vishakha
A1 Valiente-Banuet, Leopoldo
A1 Farrell, Kurt
A1 Mclean, Catriona
A1 Molina-Porcel, Laura
A1 Rajput, Alex
A1 De Deyn, Peter Paul
A1 Bastard, Nathalie Le
A1 Gearing, Marla
A1 Kaat, Laura Donker
A1 Van Swieten, John C
A1 Dopper, Elise
A1 Ghetti, Bernardino F
A1 Newell, Kathy L
A1 Troakes, Claire
A1 de Yébenes, Justo G
A1 Rábano-Gutierrez, Alberto
A1 Meller, Tina
A1 Oertel, Wolfgang H
A1 Respondek, Gesine
A1 Stamelou, Maria
A1 Arzberger, Thomas
A1 Roeber, Sigrun
A1 Müller, Ulrich
A1 Hopfner, Franziska
A1 Pastor, Pau
A1 Brice, Alexis
A1 Durr, Alexandra
A1 Ber, Isabelle Le
A1 Beach, Thomas G
A1 Serrano, Geidy E
A1 Hazrati, Lili-Naz
A1 Litvan, Irene
A1 Rademakers, Rosa
A1 Ross, Owen A
A1 Galasko, Douglas
A1 Boxer, Adam L
A1 Miller, Bruce L
A1 Seeley, Willian W
A1 Van Deerlin, Vivanna M
A1 Lee, Edward B
A1 White, Charles L
A1 Morris, Huw
A1 de Silva, Rohan
A1 Crary, John F
A1 Goate, Alison M
A1 Friedman, Jeffrey S
A1 Leung, Yuk Yee
A1 Coppola, Giovanni
A1 Naj, Adam C
A1 Wang, Li-San
A1 ,
A1 Dickson, Dennis W
A1 Höglinger, Günter U
A1 Schellenberg, Gerard D
A1 Geschwind, Daniel H
A1 Lee, Wan-Ping
YR 2024
UL http://medrxiv.org/content/early/2024/01/30/2023.12.28.23300612.abstract
AB Background Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease characterized by the accumulation of aggregated tau proteins in astrocytes, neurons, and oligodendrocytes. Previous genome-wide association studies for PSP were based on genotype array, therefore, were inadequate for the analysis of rare variants as well as larger mutations, such as small insertions/deletions (indels) and structural variants (SVs).Method In this study, we performed whole genome sequencing (WGS) and conducted association analysis for single nucleotide variants (SNVs), indels, and SVs, in a cohort of 1,718 cases and 2,944 controls of European ancestry. Of the 1,718 PSP individuals, 1,441 were autopsy-confirmed and 277 were clinically diagnosed.Results Our analysis of common SNVs and indels confirmed known genetic loci at MAPT, MOBP, STX6, SLCO1A2, DUSP10, and SP1, and further uncovered novel signals in APOE, FCHO1/MAP1S, KIF13A, TRIM24, TNXB, and ELOVL1. Notably, in contrast to Alzheimer’s disease (AD), we observed the APOE ε2 allele to be the risk allele in PSP. Analysis of rare SNVs and indels identified significant association in ZNF592 and further gene network analysis identified a module of neuronal genes dysregulated in PSP. Moreover, seven common SVs associated with PSP were observed in the H1/H2 haplotype region (17q21.31) and other loci, including IGH, PCMT1, CYP2A13, and SMCP. In the H1/H2 haplotype region, there is a burden of rare deletions and duplications (P = 6.73×10-3) in PSP.Conclusions Through WGS, we significantly enhanced our understanding of the genetic basis of PSP, providing new targets for exploring disease mechanisms and therapeutic interventions.Competing Interest StatementLaura Molina-Porcel received income from Biogen as a consultant in 2022. Gesine Respondek is now employed by Roche (Hoffmann-La Roche, Basel, Switzerland) since 2021. Her affiliation whilst completing her contribution to this manuscript was German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. Thomas G Beach is a consultant for Aprinoia Therapeutics and a Scientific Advisor and stock option holder for Vivid Genomics. Huw Morris is employed by UCL. In the last 12 months he reports paid consultancy from Roche, Aprinoia, AI Therapeutics and Amylyx; lecture fees/honoraria - BMJ, Kyowa Kirin, Movement Disorders Society. Huw Morris is a co-applicant on a patent application related to C9ORF72 - Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140). Giovanni Coppola is currently an employee of Regeneron Pharmaceuticals. Alison Goate serves on the SAB for Genentech and Muna Therapeutics.Funding StatementThis work was supported by NIH 5UG3NS104095, the Rainwater Charitable Foundation, and CurePSP. HW and PLC are supported by RF1-AG074328, P30-AG072979, U54-AG052427 and U24-AG041689. TSC is supported by NIH K08AG065519 and the Larry L Hillblom Foundation 2021-A-005-SUP. KF was supported by CurePSP 685-2023-06-Pathway and K01 AG070326. MG is supported by P30 AG066511. BFG and KLN are supported by P30 AG072976 and R01 AG080001. TGB and GES are supported by P30AG072980. IR is supported by 2R01AG038791-06A, U01NS100610, R25NS098999, U19 AG063911-1 and 1R21NS114764-01A1. OR is support by U54 NS100693. DG is supported by P30AG062429. ALB is supported by U19AG063911, R01AG073482, R01AG038791, and R01AG071756. BLM is supported by P01 AG019724, R01 AG057234 and P0544014. VMV is supported by P01-AG-066597, P01-AG-017586. HRM is supported by CurePSP, PSPA, MRC, and Michael J Fox Foundation. RDS is supported by CurePSP, PSPA, and Reta Lila Weston Trust. JFC is supported by R01 AG054008, R01 NS095252, R01 AG060961, R01 NS086736, R01 AG062348, P30 AG066514, the Rainwater Charitable Foundation / Tau Consortium, Karen Strauss Cook Research, and Scholar Award, Stuart Katz & Dr. Jane Martin. AMG is supported by the Tau Consortium and U54-NS123746. YYL is supported by U54-AG052427; U24-AG041689. LSW is supported by U01AG032984, U54AG052427, and U24AG041689. DHG is supported by 3UH3NS104095, Tau Consortium. WPL is supported by RF1-AG074328; P30-AG072979; U54-AG052427; U24-AG041689. Cases from Banner Sun Health Research Institute were supported by the NIH (U24 NS072026, P30 AG19610 and P30AG072980), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson's Research. The Mayo Clinic Brain Bank is supported through funding by NIA grants P50 AG016574, CurePSP Foundation, and support from Mayo Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data from the ADSP are available to qualified investigators via the National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) (https://dss.niagads.org/).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData from the ADSP are available to qualified investigators via the National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) (https://dss.niagads.org/). https://dss.niagads.org/